China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in the People’s Republic of China. More Details
Excellent balance sheet and good value.
Share Price & News
How has China Resources Pharmaceutical Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3320 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 3320's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 3320 underperformed the Hong Kong Pharmaceuticals industry which returned 20.3% over the past year.
Return vs Market: 3320 underperformed the Hong Kong Market which returned 28.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is China Resources Pharmaceutical Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StIs China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
4 weeks ago | Simply Wall StIs China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
2 months ago | Simply Wall StAn Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Is China Resources Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 3320 (HK$5.07) is trading below our estimate of fair value (HK$5.23)
Significantly Below Fair Value: 3320 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 3320 is good value based on its PE Ratio (9.7x) compared to the HK Pharmaceuticals industry average (12.4x).
PE vs Market: 3320 is good value based on its PE Ratio (9.7x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: 3320 is poor value based on its PEG Ratio (1.7x)
Price to Book Ratio
PB vs Industry: 3320 is good value based on its PB Ratio (0.7x) compared to the HK Pharmaceuticals industry average (1.3x).
How is China Resources Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3320's forecast earnings growth (5.7% per year) is above the savings rate (1.5%).
Earnings vs Market: 3320's earnings (5.7% per year) are forecast to grow slower than the Hong Kong market (18.4% per year).
High Growth Earnings: 3320's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3320's revenue (7.6% per year) is forecast to grow slower than the Hong Kong market (13.3% per year).
High Growth Revenue: 3320's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3320's Return on Equity is forecast to be low in 3 years time (7.3%).
How has China Resources Pharmaceutical Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3320 has high quality earnings.
Growing Profit Margin: 3320's current net profit margins (1.6%) are higher than last year (1.6%).
Past Earnings Growth Analysis
Earnings Trend: 3320's earnings have grown by 6% per year over the past 5 years.
Accelerating Growth: 3320's earnings growth over the past year (0.4%) is below its 5-year average (6% per year).
Earnings vs Industry: 3320 earnings growth over the past year (0.4%) underperformed the Pharmaceuticals industry 2.7%.
Return on Equity
High ROE: 3320's Return on Equity (6.7%) is considered low.
How is China Resources Pharmaceutical Group's financial position?
Financial Position Analysis
Short Term Liabilities: 3320's short term assets (HK$147.1B) exceed its short term liabilities (HK$122.6B).
Long Term Liabilities: 3320's short term assets (HK$147.1B) exceed its long term liabilities (HK$6.7B).
Debt to Equity History and Analysis
Debt Level: 3320's debt to equity ratio (67.9%) is considered high.
Reducing Debt: 3320's debt to equity ratio has reduced from 94.6% to 67.9% over the past 5 years.
Debt Coverage: 3320's debt is well covered by operating cash flow (21.4%).
Interest Coverage: 3320's interest payments on its debt are well covered by EBIT (3.8x coverage).
What is China Resources Pharmaceutical Group current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 3320's dividend (2.37%) is higher than the bottom 25% of dividend payers in the Hong Kong market (1.96%).
High Dividend: 3320's dividend (2.37%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 3320 has been paying a dividend for less than 10 years.
Growing Dividend: 3320's dividend payments have increased, but the company has only paid a dividend for 4 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (22.9%), 3320's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 3320's dividends in 3 years are forecast to be well covered by earnings (21.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yuewei Han (52 yo)
Mr. Yuewei Han serves as Chief Executive Officer and Executive Director at China Resources Pharmaceutical Group Limited since October 22, 2019. He has been Chief Executive Officer of China Resources Health...
CEO Compensation Analysis
Compensation vs Market: Yuewei's total compensation ($USD66.69K) is below average for companies of similar size in the Hong Kong market ($USD720.24K).
Compensation vs Earnings: Insufficient data to compare Yuewei's compensation with company performance.
Experienced Management: 3320's management team is considered experienced (4.6 years average tenure).
Experienced Board: 3320's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
China Resources Pharmaceutical Group Limited's company bio, employee growth, exchange listings and data sources
- Name: China Resources Pharmaceutical Group Limited
- Ticker: 3320
- Exchange: SEHK
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$31.855b
- Shares outstanding: 6.28b
- Website: https://www.crpharm.com
Number of Employees
- China Resources Pharmaceutical Group Limited
- China Resources Building
- 41st Floor
- Wan Chai
- Hong Kong
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products i...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/16 10:33|
|End of Day Share Price||2021/04/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.